A National Service Framework for diabetes

Department of Health. National Service Framework for coronary heart disease. London The Stationary Office 2000.

Panzram G. Mortality and survival in type 2 diabetes. Diabetologia 1987;30:123-31.

Wood D. , Durrington P. , Poulter N. , McInnes G. , Ree A. , Wray R on behalf of British Cardiac Society, British Hyperlipidemia Association, British Hypertension Society and British Diabetic Association. Joint British Recommendations on prevention on coronary heart disease in clinical practice . Heart 1998;80(suppl 2):S1-S29.

The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study Lancet 1994;344:1383-9.

Amos AF , McCarty DJ , Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997;14(suppl 5):S7-S85.

The Audit Commission. Testing Times: a review of diabetes services in England and Wales 2000 .

Winocour PH , Ainsworth A. , Williams R. Survey of secondary care services for diabetics in the United Kingdom 2000. 1: Methodology and Major Findings.

Association of British Clinical Diabetologists (ABCD) A survey of consultant-led services. Summary Results. Nov 2000.

Vaughan NJA for the Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians and the British Diabetic Association. The UK diabetes dataset; a standard for information exchange. Diabetic Med 1995 ;12:717-22.

Roxborgh M. UKDIABS Annual Report. Research Department Diabetes UK. March 2001.

Bailey CJ The Diabetes Prevention Program: headline results. Br J Diabetes Vasc Dis 2001;1:62-4.

Tuomilehto J. , Lindstrom J. , Erikksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.

The Diabetes Group and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. BMJ 1998;317:703-13.

Sanmugunathan PS , Ghahramani P. , Jackson PR et al. Aspirin for primary prevention of coronary heart disease; safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2000;85:265-71.

Currie CJ , Kraus D. , Morgan CL , Gill L. , Stott NC , Peters JR NHS acute sector expenditure of diabetes. The present, the future and excess inpatient costs of care. Diabetic Med 1997 ;14:686-92.

Alberti Kgmm , Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998;15:539-53.

Wareham NJ , Griffin SJ Should we screen for type 2 diabetes? Evaluation against National Screening Committee. BMJ 2001;322:986-8.